BIOFARMA ILAÇ SANAYI ve TICARET A.S.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
BIOFARMA ILAÇ SANAYI ve TICARET A.S. - overview
Established
1945
Location
Istanbul, -, Turkey
Primary Industry
Pharmaceuticals
About
Founded in 1945 and based in Istanbul, Turkey BIOFARMA ILAÇ SANAYI ve TICARET A. S. operates as a pharmaceutical company that manufactures generic drugs for allergies, nervous system, gastrointestinal, renal, infectious, cardiovascular, respiratory, and metabolic diseases.
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.biofarma.com.tr
Verticals
Manufacturing
Company Stage
Acquired
Total Amount Raised
Subscriber access only
BIOFARMA ILAÇ SANAYI ve TICARET A.S. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Trade Sale | Completed | BIOFARMA ILAÇ SANAYI ve TICARET A.S. | - | ||||||||
| Unspecified Exit | Completed | BIOFARMA ILAÇ SANAYI ve TICARET A.S. | - | ||||||||
| Secondary Buyout | Completed | BIOFARMA ILAÇ SANAYI ve TICARET A.S. | - | ||||||||
| Growth | Completed | BIOFARMA ILAÇ SANAYI ve TICARET A.S. | - | ||||||||
| Buyout | Completed | BIOFARMA ILAÇ SANAYI ve TICARET A.S. | - |
Displaying 1 - 5 of 5
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.